AstraZeneca, Thermo Fisher to develop develop solid tissue and blood-based companion diagnostic for Tagrisso

Calquence combination significantly improved PFS in CLL in phase III trial

Positive high-level results from an interim analysis of the AMPLIFY phase III trial showed a fixed duration of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Thermo Fisher, NCI collaborate to advance myeloid cancer research, treatment utilizing next-gen sequencing technology

To help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome, Thermo Fisher Scientific Inc. is partnering with NCI on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.

July 26, 2024

Vol.50 No.30

Clinical Roundup

Enhertu demonstrated median PFS of 13.2 months in IHC 1+ or IHC 2+/ISH- metastatic breast cancer in phase III trial

Detailed positive results from the DESTINY-Breast06 phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as IHC 0 with membrane staining] expression) following one or more lines of endocrine therapy.

June 07, 2024

Vol.50 No.23

Clinical Roundup

Enhertu improves PFS in HR-positive, HER2-low breast cancer in phase III trial

Positive high-level results from the DESTINY-Breast06 phase III trial showed that Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.

May 03, 2024

Vol.50 No.18

In Brief

Andrew Smith named chair of St. Jude Diagnostic Imaging Department

Andrew Smith was named chair of St. Jude’s Diagnostic Imaging Department. He succeeds Beth McCarville, who was interim chair of the department since the death of Zoltan Patay, who held the position from 2017 to 2022.

April 19, 2024

Vol.50 No.16

Drugs & Targets

FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors

FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

April 12, 2024

Vol.50 No.15

AstraZeneca, Thermo Fisher to develop develop solid tissue and blood-based companion diagnostic for Tagrisso

YOU MAY BE INTERESTED IN

Calquence combination significantly improved PFS in CLL in phase III trial

Thermo Fisher, NCI collaborate to advance myeloid cancer research, treatment utilizing next-gen sequencing technology

Enhertu demonstrated median PFS of 13.2 months in IHC 1+ or IHC 2+/ISH- metastatic breast cancer in phase III trial

Enhertu improves PFS in HR-positive, HER2-low breast cancer in phase III trial

Andrew Smith named chair of St. Jude Diagnostic Imaging Department

FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors

Renew today!

Subscriber content

Login